The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4

Exclusion Criteria

• •1\. Documented poorly controlled diabetes mellitus, poorly controlled hypertension, malignant tumour, or any clinically significant unstable medical condition;
• •2\. Active dysphagia or swallowing disorder; or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation;
• •3\. Known hypersensitivity to sevelamer or any constituents of the study drug;
• •4\. Unable to comply with the requirements of the study;
• •5\. Hypophosphatemia (serum phosphorus level \<0.87mmol/L);
• •6\. Women who have a positive pregnancy test at enrollment or women who are breast-feeding;
• •7\. Have been enrolled in other interventional study;
• •8\. Received sevelamer or other intestinal adsorbents, or broad-spectrum antibiotic within one month prior to the screening period.